TrialMovement disorders : official journal of the Movement Disorder Society2022

Phase 1/1b Studies of UCB0599, an Oral Inhibitor of α-Synuclein Misfolding, Including a Randomized Study in Parkinson's Disease.

Johan Willem Smit et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.